Contemporary Management of Pineoblastoma

Matthew C. Tate, Martin J. Rutkowski, Andrew T. Parsa*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

22 Scopus citations


Pineoblastomas (PBs) represent the most aggressive of the pineal parenchymal tumors. Routine treatment consists of operative management of obstructive hydrocephalus and cerebrospinal fluid studies followed by maximal resection and adjuvant chemotherapy/radiotherapy, resulting in a median survival of 20 months. Important prognostic factors for survival of patients with PB include extent of resection, age at presentation, disseminated disease, and craniospinal radiotherapy. Novel strategies being evaluated for the treatment of PB include high-dose chemotherapy with autologous stem cell therapy, stereotactic radiosurgery, and histone deacetylase inhibitors.

Original languageEnglish (US)
Pages (from-to)409-412
Number of pages4
JournalNeurosurgery Clinics of North America
Issue number3
StatePublished - Jul 1 2011


  • Pineoblastoma
  • Survival
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery


Dive into the research topics of 'Contemporary Management of Pineoblastoma'. Together they form a unique fingerprint.

Cite this